Barclays
LXEO icon

Barclays’s Lexeo Therapeutics LXEO Stock Holding History

Barclays’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.8K Sell
12,165
-176,589
-94% -$1.25M ﹤0.01% 4180
2025
Q4 		$1.87M Buy
188,754
+77,175
+69% +$704K ﹤0.01% 2981
2025
Q3 		$741K Sell
111,579
-4,563
-4% -$22.1K ﹤0.01% 3553
2025
Q2 		$467K Buy
116,142
+69,475
+149% +$228K ﹤0.01% 3792
2025
Q1 		$162K Sell
46,667
-8,494
-15% -$37.6K ﹤0.01% 4159
2024
Q4 		$363K Buy
55,161
+4,951
+10% +$39K ﹤0.01% 4017
2024
Q3 		$454K Buy
50,210
+31,057
+162% +$370K ﹤0.01% 3842
2024
Q2 		$307K Sell
19,153
-3,776
-16% -$54.8K ﹤0.01% 3333
2024
Q1 		$360K Buy
22,929
+7,412
+48% +$116K ﹤0.01% 3788
2023
Q4 		$208K Buy
+15,517
New +$193K ﹤0.01% 4401

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's LXEO Position: Q1 2026 in Review

Barclays reduced its Lexeo Therapeutics (LXEO) stake by 94% in Q1 2026, selling an estimated $1.25M and leaving 12,165 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4180.

Barclays first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.87M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Barclays held 12,165 shares of Lexeo Therapeutics worth $69.8K as of Q1 2026.
  • Barclays sold 176,589 Lexeo Therapeutics shares in Q1 2026, an estimated $1.25M.
  • Lexeo Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4180 holding.
  • Barclays first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Barclays's Lexeo Therapeutics position peaked at $1.87M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.